StockNASDAQ · US · USDHealthcare · Medical Instruments & Supplies
$XRAY
DENTSPLY SIRONA Inc.
DENTSPLY SIRONA develops, manufactures, and markets dental products and technologies for dental professionals, as well as healthcare consumables for urinary and bowel management. Headquartered in Charlotte, North Carolina, it sells products through foreign subsidiaries to customers in approximately 140 countries. The company operates four segments: Connected Technology Solutions, which includes dental equipment, instruments, CAD/CAM products, and the DS Core cloud platform; Essential Dental Solutions, which includes endodontic, restorative, preventive, and small equipment products; Orthodontic and Implant Solutions, which includes SureSmile clear aligners, digital orthodontic services, implants, prosthetics, and digital dentures; and Wellspect Healthcare, which offers catheters and irrigation systems. DENTSPLY SIRONA sells dental products through third-party distributors and, for certain products, directly to laboratories or dental professionals. Its continence care products are sold primarily through medical-supply distributors, with some direct sales to patients and medical providers.
UBS kept Dentsply Sirona at Buy but reduced its price target to $13 from $17, a 23.5% cut. This implies a 41.9% upside from the Nov 13 close of $9.16. Recent analyst targets range from $10 to $13.
XRAY reported Q3 2026 revenue of $836M, missing estimates by 2.7%, with adjusted EPS of $0.29, missing by 6.2%. The company cut full-year revenue guidance to $3.5B and adjusted EPS to $1.25. Growth in Wellspect Healthcare and U.S. dental segments was offset by inventory reductions and market challenges in EMEA and the Middle East. Management highlighted cost-saving initiatives and investments in sales and education.
DENTSPLY SIRONA (XRAY) reduced its 2026 guidance. Analysts previously viewed the stock as 24% undervalued, but this adjustment may impact that assessment. The change in outlook could influence investor decisions.
via TradingView
XRAY sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 1 news story mentioning XRAY (DENTSPLY SIRONA Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent XRAY coverage spans earnings, financial news and market movers.
What's driving XRAY
The target cut likely pressures near-term sentiment, even though the rating stays Buy.
JP Morgan retained its Neutral rating for Dentsply Sirona but reduced its price target to $10 from $12, a 16.7% decrease. This implies a 5.7% upside from the Nov 6 close of $9.46. Recent analyst targets for the company range from $10 to $13.
AlphAI scores every news story that mentions XRAY with an AI model for sentiment and relevance, and aggregates insider trades from DENTSPLY SIRONA Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
UBS kept Dentsply Sirona at Buy but reduced its price target to $13 from $17, a 23.5% cut. This implies a 41.9% upside from the Nov 13 close of $9.16. Recent analyst targets range from $10 to $13.
XRAY reported Q3 2026 revenue of $836M, missing estimates by 2.7%, with adjusted EPS of $0.29, missing by 6.2%. The company cut full-year revenue guidance to $3.5B and adjusted EPS to $1.25. Growth in Wellspect Healthcare and U.S. dental segments was offset by inventory reductions and market challenges in EMEA and the Middle East. Management highlighted cost-saving initiatives and investments in sales and education.
DENTSPLY SIRONA (XRAY) reduced its 2026 guidance. Analysts previously viewed the stock as 24% undervalued, but this adjustment may impact that assessment. The change in outlook could influence investor decisions.
JP Morgan retained its Neutral rating for Dentsply Sirona but reduced its price target to $10 from $12, a 16.7% decrease. This implies a 5.7% upside from the Nov 6 close of $9.46. Recent analyst targets for the company range from $10 to $13.
DENTSPLY SIRONA reported Q3 earnings with a $39M pretax accounting benefit, not expected to recur. Operating cash flow declined to $32M. Wellspect Healthcare revenue rose 10%, while dental segments saw declines. The company repurchased 1.2M shares and plans $120M in savings for 2026. Management expects continued investment in growth areas.
Dentsply Sirona (XRAY) reported Q3 2026 revenue of $836M, missing estimates by 2.7% and down 7.5% YoY. Adjusted EPS was $0.29, missing estimates by 6.2%. Adjusted EBITDA beat estimates by 4.7%. The company lowered its full-year revenue and EPS guidance. Operating margin improved to 4.4%, while free cash flow margin dropped to 0%.
DENTSPLY SIRONA Inc. (XRAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Dentsply Sirona Reports Third Quarter 2026 Results News Summary • Q3 2026 net sales of $836 million • Q3 2026 GAAP gross margin of 52.9%, GAAP diluted loss per share of ($0.01) • Q3 2026 adjusted gross margin of 54.5%, adjusted EBITDA margin of 17.3%, adjusted EPS of $0.29 • Achi
Shares of Stryker, Omnicell, Zimmer Biomet, Artivion, and Dentsply Sirona surged after Democrats reclaimed majorities in the House and Senate, easing regulatory uncertainty around drug pricing. Analysts expect the biopharmaceutical sector to strengthen. Stryker (SYK) rose 8.8%, Omnicell (OMCL) 10.8%, Zimmer Biomet (ZBH) 15.2%, Artivion (AORT) 9.1%, and Dentsply Sirona (XRAY) 9.2%. Zimmer Biomet's shares hit a 52-week high of $111.96.
Dentsply Sirona (XRAY) is set to report Q3 earnings. Last quarter, it beat revenue and EPS estimates, with revenue at $898M, down 4.1% YoY. Analysts expect Q3 revenue to decline 4.9% YoY. The stock is up 14.1% over the last month, with an average price target of $12.40.
Henry Schein (HSIC) reported Q2 revenues of $3.46B, up 6.7% YoY, beating estimates. Envista (NVST) saw 7.1% YoY growth, while Align Tech (ALGN) and Dentsply Sirona (XRAY) reported mixed results. Sector stocks are down 18.3% on average since earnings.